Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
NCT00811863 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-08-02
Summary
The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency (eGFR 30-59) and severe renal insufficiency or end-stage renal disease requiring dialysis (eGFR \<30).
Conditions
- Nephrogenic Systemic Fibrosis
- Renal Insufficiency
Sponsors & Collaborators
-
Guerbet
lead INDUSTRY
Principal Investigators
-
Herbert R. Neuman, MD · Mallinckrodt
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2012-05-17
- Completion
- 2012-05-17
Countries
- United States
Study Locations
More Related Trials
-
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
NCT04776187 ·Status: UNKNOWN ·Phase: PHASE4
-
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
NCT00883636 ·Status: TERMINATED
-
The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
NCT03108924 ·Status: COMPLETED ·Phase: PHASE1
-
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
NCT06939816 ·Status: TERMINATED ·Phase: PHASE2
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438 ·Status: RECRUITING ·Phase: NA
-
Study of GBT021601 in Participants With Renal Impairment
NCT05878704 ·Status: TERMINATED ·Phase: PHASE1
-
Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome
NCT06797609 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
NCT00600951 ·Status: COMPLETED
-
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
NCT03832114 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia
NCT01481610 ·Status: TERMINATED ·Phase: PHASE2
-
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
NCT04154670 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
NCT03703908 ·Status: TERMINATED ·Phase: PHASE2
-
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
NCT00908310 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Gadoterate in Patients With Renal Dysfunction
NCT02382380 ·Status: TERMINATED ·Phase: PHASE4
-
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
NCT00464321 ·Status: COMPLETED ·Phase: PHASE1
-
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
NCT04877847 ·Status: TERMINATED ·Phase: NA
-
Rituximab to Prevent Recurrence of Proteinuria
NCT01164098 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
NCT00600834 ·Status: COMPLETED
-
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
NCT04387448 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT03448692 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
NCT06586216 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects
NCT00805090 ·Status: COMPLETED ·Phase: PHASE1
-
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
NCT00843349 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
NCT02959138 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
NCT03581591 ·Status: COMPLETED ·Phase: PHASE3